Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.

@article{Kearns2003CisaprideDI,
  title={Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.},
  author={Gregory L. Kearns and Patricia Robinson and John T Wilson and Deanna Wilson-Costello and Gail R Knight and R. Matthew Ward and Johannes N van den Anker},
  journal={Clinical pharmacology and therapeutics},
  year={2003},
  volume={74 4},
  pages={312-25}
}
BACKGROUND Cisapride, a prokinetic agent and substrate for cytochrome P450 (CYP) 3A4, has been used to treat neonates and infants with feeding intolerance and apnea or bradycardia associated with gastroesophageal reflux. At age 1 month, CYP3A4 activity has been reported to be only 30% to 40% of adult activity. This known developmental delay in the expression of CYP3A4 prompted us to conduct a classical open-label pharmacokinetic study of cisapride in neonates and young infants. METHODS A… CONTINUE READING